Temsirolimus
Title: Temsirolimus
CAS Registry Number: 162635-04-3
CAS Name: Rapamycin 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]
Additional Names: rapamycin 42-ester with 2,2-bis-(hydroxymethyl)propionic acid
Manufacturers' Codes: CCI-779
Molecular Formula: C56H87NO16
Molecular Weight: 1030.29
Percent Composition: C 65.28%, H 8.51%, N 1.36%, O 24.85%
Literature References: Ester analog of rapamycin, q.v.; selectively inhibits mammalian target of rapamycin (mTOR). Prepn: J. S. Skotnicki et al., US 5362718 (1994 to Am. Home Prod.). Lipase-catalyzed synthesis from rapamycin: J. Gu et al., Org. Lett. 7, 3945 (2005). Clinical pharmacology: E. Raymond et al., J. Clin. Oncol. 22, 2336 (2004). Clinical study in advanced refractory renal cell carcinoma: M. B. Atkins et al., ibid. 909. Clinical evaluation in glioblastoma multiforme: E. Galanis et al., J. Clin. Oncol. 23, 5294 (2005); in breast cancer: S. Chan et al., ibid. 5314; in mantle cell lymphoma: T. E. Witzig et al., ibid. 5347.
Properties: White solid. Sol in water. Lipophilic.
Therap-Cat: Antineoplastic.
Keywords: Antineoplastic; Antibiotics and Analogs.

Others monographs:
SulfaguanidineCuprous SelenideVerapamil2,2'-Azobisisobutyronitrile
HalazepamGalliumThioxantheneFibronectins
Menthyl SalicylateAcid FuchsinDiethylstilbestrolSodium Oxide
BiopterinHexacarbacholine BromideEpicholestanolNitracrine
©2016 DrugLead US FDA&EMEA